<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684489</url>
  </required_header>
  <id_info>
    <org_study_id>11023</org_study_id>
    <secondary_id>HR# 11023</secondary_id>
    <nct_id>NCT00684489</nct_id>
  </id_info>
  <brief_title>Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension</brief_title>
  <acronym>Renin</acronym>
  <official_title>Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled or Complicated Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate&#xD;
      in elevating blood pressure and are useful in selecting effective antihypertensive&#xD;
      therapy.2,3&#xD;
&#xD;
      The researchers hypothesize that:&#xD;
&#xD;
        1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure&#xD;
           control in patients with untreated hypertension as well as in patients with treatment&#xD;
           refractory or resistant hypertension that are managed by Clinical Hypertension&#xD;
           Specialists.&#xD;
&#xD;
        2. Renin-guided therapeutics will reduce the number of medications required to maintain&#xD;
           blood pressure control to &lt;140/90 mmHg in hypertensive patients receiving 3 or more&#xD;
           medications, while under the care of a Clinical Hypertension Specialist.&#xD;
&#xD;
        3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care&#xD;
           provided by Clinical Hypertension Specialists.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension affects ~25% of adults. The prevalence of hypertension and related complications&#xD;
      is greater among the elderly, obese, and ethnic minorities. Unfortunately, hypertension&#xD;
      control rates remain in the 25% range and are often significantly lower for the high-risk&#xD;
      groups noted.1 Since the high-risk groups are growing more rapidly than the general&#xD;
      population, the prevalence of hypertension and associated morbidity and mortality will&#xD;
      probably increase sharply in the years ahead unless successful strategies are implemented for&#xD;
      dramatically improving blood pressure control.&#xD;
&#xD;
      Direct measurements of plasma renin reflect the relative balance between volume (V) and&#xD;
      vasoconstrictor (renin [R]) factors underlying the elevated blood pressure in patients with&#xD;
      essential hypertension.2 While many antihypertensive medications have effects on both the&#xD;
      volume (V) and vasoconstrictor (renin [R]) components of elevated blood pressure, one or the&#xD;
      other usually predominates&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A; B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A is clinical hypertension specialist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A is assigned to a clinical hypertension specialist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B is renin-guided therapeutics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be assigned to renin-guided therapeutics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clinical hypertension specialist-no specific med. Any anti-hypertension meds.</intervention_name>
    <description>assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>A is clinical hypertension specialist</arm_group_label>
    <arm_group_label>A; B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>renin guided therapeutics-no specific med. Any anti-hypertensive med.</intervention_name>
    <description>renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>A; B</arm_group_label>
    <arm_group_label>Arm B is renin-guided therapeutics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age, 21 years of age and older&#xD;
&#xD;
          -  Male or female (post-menopausal or effective method of birth control)&#xD;
&#xD;
          -  BP and treatment criteria noted above&#xD;
&#xD;
          -  Willingness to provide written, informed consent&#xD;
&#xD;
          -  Ability to adhere to study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes or hyperlipidemia requiring medication changes&#xD;
&#xD;
          -  Any active disease process requiring new diagnostic and therapeutic plans&#xD;
&#xD;
          -  Any life-threatening illness&#xD;
&#xD;
          -  History of alcohol or drug abuse in past 5 years&#xD;
&#xD;
          -  Mental illness or personality disorder that interfere with adherence to study protocol&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 mg/dL unless documented stable for at least one year&#xD;
&#xD;
          -  Dialysis for chronic renal failure, even if creatinine stable for at least one year&#xD;
&#xD;
          -  Intolerance to two or more classes of antihypertensive medications&#xD;
&#xD;
          -  Normal home BP (&lt;140/90 mmHg at baseline), i.e., office only hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>May 22, 2008</last_update_submitted>
  <last_update_submitted_qc>May 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Brent M. Egan, MD</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>renin-guided therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

